Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
1(100.0%)
1Total
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05754138Recruiting

Safety of Sports for Patients With a Subcutaneous Implantable Cardioverter Defibrillator

Role: lead

NCT05578313Unknown

Inflammatory Bowel Diseases (IBD) Cannabis Registry

Role: lead

NCT05554445Unknown

Observational Investigation of the CDED in a Real World IBD Clinic

Role: lead

NCT04969172Phase 2Unknown

A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 to Prevent Clinical Deterioration in Patients With Moderate or Severe COVID-19 Infection

Role: lead

NCT01926691Completed

Predictors for Poststroke Outcomes: Tel Aviv Brain Acute Stroke Cohort Acute Stroke Cohort (TABASCO)

Role: lead

All 5 trials loaded